LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Solit, David"
  2. AU="Raymond, Benjamin"
  3. AU="Maddi, Abhiram"
  4. AU="Rodríguez, Johanna G"
  5. AU="Frans, J"
  6. AU="Elisa Palazzari"

Suchergebnis

Treffer 1 - 10 von insgesamt 368

Suchoptionen

  1. Artikel ; Online: BRAF Mutations: The Discovery of Allele- and Lineage-Specific Differences.

    Hanrahan, Aphrothiti J / Solit, David B

    Cancer research

    2022  Band 82, Heft 1, Seite(n) 12–14

    Abstract: Cancer treatment is increasingly guided by molecular analyses designed to identify clinically actionable genomic alterations in individual patients. The discovery ... ...

    Abstract Cancer treatment is increasingly guided by molecular analyses designed to identify clinically actionable genomic alterations in individual patients. The discovery of
    Mesh-Begriff(e) Alleles ; Humans ; Melanoma/drug therapy ; Melanoma/genetics ; Mutation ; Precision Medicine ; Protein Kinase Inhibitors ; Proto-Oncogene Proteins B-raf/genetics
    Chemische Substanzen Protein Kinase Inhibitors ; BRAF protein, human (EC 2.7.11.1) ; Proto-Oncogene Proteins B-raf (EC 2.7.11.1)
    Sprache Englisch
    Erscheinungsdatum 2022-01-04
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 1432-1
    ISSN 1538-7445 ; 0008-5472
    ISSN (online) 1538-7445
    ISSN 0008-5472
    DOI 10.1158/0008-5472.CAN-21-3377
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: BRAF - a tumour-agnostic drug target with lineage-specific dependencies.

    Hanrahan, Aphrothiti J / Chen, Ziyu / Rosen, Neal / Solit, David B

    Nature reviews. Clinical oncology

    2024  Band 21, Heft 3, Seite(n) 224–247

    Abstract: In June 2022, the FDA granted Accelerated Approval to the BRAF inhibitor dabrafenib in combination with the MEK inhibitor trametinib for the treatment of adult and paediatric patients (≥6 years of age) with unresectable or metastatic ... ...

    Abstract In June 2022, the FDA granted Accelerated Approval to the BRAF inhibitor dabrafenib in combination with the MEK inhibitor trametinib for the treatment of adult and paediatric patients (≥6 years of age) with unresectable or metastatic BRAF
    Mesh-Begriff(e) Adult ; Humans ; Child ; Proto-Oncogene Proteins B-raf/genetics ; Neoplasms/drug therapy ; Neoplasms/genetics ; Neoplasms/chemically induced ; Imidazoles/therapeutic use ; Oximes/adverse effects ; Mitogen-Activated Protein Kinase Kinases/genetics ; Mutation ; Protein Kinase Inhibitors/therapeutic use ; Protein Kinase Inhibitors/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
    Chemische Substanzen dabrafenib (QGP4HA4G1B) ; Proto-Oncogene Proteins B-raf (EC 2.7.11.1) ; Imidazoles ; Oximes ; Mitogen-Activated Protein Kinase Kinases (EC 2.7.12.2) ; Protein Kinase Inhibitors ; BRAF protein, human (EC 2.7.11.1)
    Sprache Englisch
    Erscheinungsdatum 2024-01-26
    Erscheinungsland England
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2491410-1
    ISSN 1759-4782 ; 1759-4774
    ISSN (online) 1759-4782
    ISSN 1759-4774
    DOI 10.1038/s41571-023-00852-0
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: Clinical cancer genomic profiling.

    Chakravarty, Debyani / Solit, David B

    Nature reviews. Genetics

    2021  Band 22, Heft 8, Seite(n) 483–501

    Abstract: Technological innovation and rapid reduction in sequencing costs have enabled the genomic profiling of hundreds of cancer-associated genes as a component of routine cancer care. Tumour genomic profiling can refine cancer subtype classification, identify ... ...

    Abstract Technological innovation and rapid reduction in sequencing costs have enabled the genomic profiling of hundreds of cancer-associated genes as a component of routine cancer care. Tumour genomic profiling can refine cancer subtype classification, identify which patients are most likely to benefit from systemic therapies and screen for germline variants that influence heritable cancer risk. Here, we discuss ongoing efforts to enhance the clinical utility of tumour genomic profiling by integrating tumour and germline analyses, characterizing allelic context and identifying mutational signatures that influence therapy response. We also discuss the potential clinical utility of more comprehensive whole-genome and whole-transcriptome sequencing and ultra-sensitive cell-free DNA profiling platforms, which allow for minimally invasive, serial analyses of tumour-derived DNA in blood.
    Mesh-Begriff(e) Biomarkers, Tumor/genetics ; DNA, Neoplasm ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Genes, Neoplasm ; Genome, Human ; Germ-Line Mutation ; Humans ; Mutation ; Neoplasms/genetics
    Chemische Substanzen Biomarkers, Tumor ; DNA, Neoplasm
    Sprache Englisch
    Erscheinungsdatum 2021-03-24
    Erscheinungsland England
    Dokumenttyp Journal Article ; Research Support, N.I.H., Extramural ; Review
    ZDB-ID 2035157-4
    ISSN 1471-0064 ; 1471-0056
    ISSN (online) 1471-0064
    ISSN 1471-0056
    DOI 10.1038/s41576-021-00338-8
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: Overcoming Adaptive Resistance to KRAS Inhibitors Through Vertical Pathway Targeting.

    Yaeger, Rona / Solit, David B

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2020  Band 26, Heft 7, Seite(n) 1538–1540

    Abstract: KRAS G12C inhibitors have shown promise in KRAS G12C-mutant lung cancer but intrinsic and acquired resistance are common. Cotreatment with inhibitors of the protein phosphatase SHP2 can abrogate the adaptive response of cancer cells to KRAS inhibitors ... ...

    Abstract KRAS G12C inhibitors have shown promise in KRAS G12C-mutant lung cancer but intrinsic and acquired resistance are common. Cotreatment with inhibitors of the protein phosphatase SHP2 can abrogate the adaptive response of cancer cells to KRAS inhibitors resulting in greater suppression of MAPK signaling and enhanced tumor growth inhibition.
    Mesh-Begriff(e) Cell Line, Tumor ; Feedback ; Humans ; Lung Neoplasms ; Mutation ; Proto-Oncogene Proteins p21(ras)
    Chemische Substanzen KRAS protein, human ; Proto-Oncogene Proteins p21(ras) (EC 3.6.5.2)
    Sprache Englisch
    Erscheinungsdatum 2020-01-30
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, N.I.H., Extramural ; Comment
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-19-4060
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel ; Online: Precision Oncology: Three Small Steps Forward.

    Wise, Hannah C / Solit, David B

    Cancer cell

    2019  Band 35, Heft 6, Seite(n) 825–826

    Abstract: Only a subset of cancer patients currently benefit from personalized treatment approaches. Detection of actionable drug targets in cell-free DNA, more comprehensive molecular profiling integrating transcriptional analyses, and personalized combination ... ...

    Abstract Only a subset of cancer patients currently benefit from personalized treatment approaches. Detection of actionable drug targets in cell-free DNA, more comprehensive molecular profiling integrating transcriptional analyses, and personalized combination regimens all hold promise in expanding the benefits of personalized oncology to larger numbers of cancer patients.
    Mesh-Begriff(e) Humans ; Neoplasms ; Patient Selection ; Precision Medicine
    Sprache Englisch
    Erscheinungsdatum 2019-06-10
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Comment
    ZDB-ID 2078448-X
    ISSN 1878-3686 ; 1535-6108
    ISSN (online) 1878-3686
    ISSN 1535-6108
    DOI 10.1016/j.ccell.2019.05.009
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  6. Artikel ; Online: Lessons from the Study of Exceptional Responders.

    Elzein, Arijh / Iyer, Gopa / Solit, David B

    Cancer cell

    2021  Band 39, Heft 1, Seite(n) 11–13

    Abstract: In this issue of Cancer Cell, Wheeler et al. report that mechanisms of exceptional response to cancer treatment can be grouped into four broad categories: dysregulated intracellular signaling pathways, altered DNA damage response, tumor microenvironment ... ...

    Abstract In this issue of Cancer Cell, Wheeler et al. report that mechanisms of exceptional response to cancer treatment can be grouped into four broad categories: dysregulated intracellular signaling pathways, altered DNA damage response, tumor microenvironment or immune engagement, and alterations associated with a favorable prognosis.
    Mesh-Begriff(e) Humans ; Neoplasms/drug therapy ; Neoplasms/genetics ; Prognosis ; Signal Transduction ; Tumor Microenvironment
    Sprache Englisch
    Erscheinungsdatum 2021-01-09
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, N.I.H., Extramural ; Comment
    ZDB-ID 2078448-X
    ISSN 1878-3686 ; 1535-6108
    ISSN (online) 1878-3686
    ISSN 1535-6108
    DOI 10.1016/j.ccell.2020.11.008
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  7. Artikel ; Online: Opportunities and Challenges in Genomic Sequencing for Precision Cancer Care.

    Cheng, Michael L / Solit, David B

    Annals of internal medicine

    2018  Band 168, Heft 3, Seite(n) 221–222

    Mesh-Begriff(e) Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Agents, Immunological/therapeutic use ; Biomarkers, Tumor/genetics ; Gene Expression Profiling ; Genomics/methods ; Humans ; Neoplasms/genetics ; Neoplasms/therapy ; Precision Medicine ; Sequence Analysis, DNA
    Chemische Substanzen Antibodies, Monoclonal, Humanized ; Antineoplastic Agents, Immunological ; Biomarkers, Tumor ; pembrolizumab (DPT0O3T46P)
    Sprache Englisch
    Erscheinungsdatum 2018-01-09
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Review
    ZDB-ID 336-0
    ISSN 1539-3704 ; 0003-4819
    ISSN (online) 1539-3704
    ISSN 0003-4819
    DOI 10.7326/M17-2940
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  8. Artikel ; Online: Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation.

    Gounder, Mrinal M / Solit, David B / Tap, William D

    The New England journal of medicine

    2018  Band 378, Heft 20, Seite(n) 1945–1947

    Mesh-Begriff(e) Histiocytic Sarcoma/diagnostic imaging ; Histiocytic Sarcoma/drug therapy ; Histiocytic Sarcoma/genetics ; Humans ; MAP Kinase Kinase 1/genetics ; Male ; Metabolic Networks and Pathways ; Middle Aged ; Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors ; Mitogen-Activated Protein Kinase Kinases/metabolism ; Mutation ; Protein Kinase Inhibitors/therapeutic use ; Pyridones/therapeutic use ; Pyrimidinones/therapeutic use
    Chemische Substanzen Protein Kinase Inhibitors ; Pyridones ; Pyrimidinones ; trametinib (33E86K87QN) ; MAP Kinase Kinase 1 (EC 2.7.12.2) ; MAP2K1 protein, human (EC 2.7.12.2) ; Mitogen-Activated Protein Kinase Kinases (EC 2.7.12.2)
    Sprache Englisch
    Erscheinungsdatum 2018-05-16
    Erscheinungsland United States
    Dokumenttyp Case Reports ; Letter
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMc1511490
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  9. Artikel ; Online: Tumor Genetic Screening Programs: A Call to Action.

    Hyman, David M / Solit, David B

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2015  Band 33, Heft 25, Seite(n) 2725–2726

    Mesh-Begriff(e) Biomarkers, Tumor/genetics ; Clinical Trials as Topic ; Female ; Genetic Testing ; Genotype ; Humans ; Male ; Mutation ; Neoplasms/genetics ; Patient Selection
    Chemische Substanzen Biomarkers, Tumor
    Sprache Englisch
    Erscheinungsdatum 2015-09-01
    Erscheinungsland United States
    Dokumenttyp Comment ; Editorial
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.2015.61.9296
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  10. Artikel ; Online: "Primary" and "secondary" muscle-invasive bladder cancer is more than just a surrogate for molecular subtypes.

    Pietzak, Eugene J / Al-Ahmadie, Hikmat / Walasek, Aleksandra / Bajorin, Dean F / Rosenberg, Jonathan E / Bochner, Bernard H / Solit, David B / Iyer, Gopa

    Translational cancer research

    2022  Band 8, Heft Suppl 6, Seite(n) S642–S644

    Sprache Englisch
    Erscheinungsdatum 2022-01-15
    Erscheinungsland China
    Dokumenttyp Journal Article
    ZDB-ID 2901601-0
    ISSN 2219-6803 ; 2218-676X
    ISSN (online) 2219-6803
    ISSN 2218-676X
    DOI 10.21037/tcr.2019.12.21
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang